Download PDF
Synlett 2003(15): 2404-2406  
DOI: 10.1055/s-2003-43343
LETTER
© Georg Thieme Verlag Stuttgart · New York

Solid Phase Synthesis of 1,2-Disubstituted Alkenes: A Novel Alkynyldihydropyridine to Alkenylpyridine Isomerization

Chixu Chen*, Bowei Wang, Benito Munoz
Merck Research Laboratories San Diego, 3535 General Atomics Court, San Diego, CA 92131, USA
Fax: +1(858)2025743; e-Mail: chixu_chen@merck.com ;
Further Information

Publication History

Received 14 August 2003
Publication Date:
21 November 2003 (online)

    Permissions and Reprints All articles of this category

Abstract

A series of 1,2-disubstituted pyridylalkenes have been prepared using a solid-phase resin approach. This approach takes advantage of a novel alkynyldihydropyridine to alkenylpyridine isomerization.

Key words

solid-phase synthesis - 1,2-disubstituted alkenes - alkynyldihydropyridine - alkenylpyridine - isomerization

    References

  • 1a Bhattacharyya S. Curr. Med. Chem.  2001,  8:  1383 
    Google Scholar
  • 1b Lou B. Drug Discovery Today  2001,  6:  1288 
    Google Scholar
  • 1c Sammelson RE. Kurth MJ. Chem. Rev.  2001,  101:  137 
    Google Scholar
  • 1d Baldwin JJ. Comb. Chem. Mol. Diversity Drug Discovery  1998,  181 
    Google Scholar
  • 2a Munoz B. Chen C. McDonald IA. Biotechnology  2000,  71:  78 
    CrossrefGoogle Scholar
  • 2b Chen C. Munoz B. Tetrahedron Lett.  1999,  40:  3491 
    CrossrefGoogle Scholar
  • 2c Chen C. Munoz B. Tetrahedron Lett.  1998,  39:  6781 
    CrossrefGoogle Scholar
  • 2d Chen C. Munoz B. Tetrahedron Lett.  1998,  39:  3401 
    CrossrefGoogle Scholar
  • 2e Chen C. McDonald IA. Munoz B. Tetrahedron Lett.  1998,  39:  217 
    CrossrefGoogle Scholar
  • 3a Pin J.-F. Curr. Drug Targets: CNS Neurol. Disord.  2002,  1(3):  297 
    CrossrefGoogle Scholar
  • 3b Varney MA. Cosford ND. Jachec C. Rao SP. Sacaan A. Lin F.-F. Bleicher LS. Santori EM. Flor PJ. Allgeier H. Gasparini F. Kuhn R. Hess SD. Velicelebi G. Johnson EC. J. Pharmacol. Exp. Ther.  1999,  290:  170 
    CrossrefGoogle Scholar
  • 3c Gasparini F. Lingenhohl K. Stoehr N. Flor PJ. Heinrich M. Vranesic I. Biollaz M. Allgeier H. Hechendorn R. Urwyler S. Varney MA. Johnson EC. Hess SD. Rao SP. Sacaan AI. Santori EM. Velicelebi G. Kuhn R. Neuropharmacology  1999,  38:  1493 
    CrossrefGoogle Scholar
  • 8 An isoxazolinocyclobutenone to isoxazolocyclobutanone isomerization both in solution and solid-phase was reported, see: Cheng W.-C. Wong M. Olmstead MM. Kurth MJ. Org. Lett.  2002,  4(3):  741 
    Google Scholar
4

Benzyl 6-methyl-2-(phenylethynyl)pyridine-1(2 H )-carboxylate ( 4b): 1H NMR (3:1 THF d8 /CD3OD): δ = 7.43-7.25 (10 H, m), 5.98-5.93 (1 H, m), 5.89-5.87 (1 H, d), 5.75-5.70 (1 H, m) 5.54-5.52 (1 H, m), 5.25-5.16 (2 H, m), 2.17 (3 H, s). 13C NMR (3:1 THF d8 /CD3OD): δ = 154.55, 137.49, 136.16, 132.69, 129.51, 129.51, 129.36, 129.32, 129.20, 124.31, 124.05, 120.70, 112.79, 87.72, 83.34, 68.85, 45.78, 22.17. ESMS (M + Na+): 352.

5

Resin-bound Benzyl 6-methyl-2-(phenylethynyl)pyri-dine-1(2 H )-carboxylate ( 4a): IR (KBr): 2221, 1714 cm-1.
Resin-bound Benzyl 2-(phenylethynyl)pyridine-1(2 H )-carboxylate ( 4d): IR (KBr): 2231, 1724 cm-1.
Resin-bound Benzyl 4-methoxy-2-(phenylethynyl)pyri-dine-1(2 H )-carboxylate ( 4e): IR (KBr): 2241, 1724, 1662 cm-1.
Resin-bound Benzyl 4-hydroxy-2-(phenylethynyl)pyri-dine-1(2 H )-carboxylate ( 4f): IR (KBr): 2221, 1734, 1683, 1605 cm-1.
Resin-bound Benzyl 3-methoxy-2-(phenylethynyl)pyri-dine-1(2 H )-carboxylate ( 4h): IR (KBr): 2221, 1716, 1660 cm-1.
Resin-bound Benzyl 6-methyl-2-prop-1-ynylpyridine-1(2 H )-carboxylate ( 4k): IR (KBr): 2240, 1719 cm-1.

6

General Procedure for Synthesis of Ethenylpyridine; 2-Methyl-6-[( E )-2-phenylethenyl]pyridine ( 6a): To 2-picoline (118 mg, 1.5 equiv) was added phenylethynyl-magnesium bromide (0.5 M in THF, 10 mL, 5 equiv). The resulting solution was added to resin-bound chloroformate (1 g, 1 mmol/g) in polypropylene tube fitted with a frit. The tube was capped and the reaction was agitated for 15 min. The resin was filtered and washed with THF, THF/H2O 1:1, THF, MeOH, CH2Cl2 and THF. The resin was re-suspended in THF and NaOMe (4.4 M in MeOH, 0.23 mL, 1 equiv) was added. The resulting suspension was agitated for 3 h. The resin was filtered and washed with THF (3 ×). The combined filtrates were concentrated. Prep-TLC purification gave (E)-2-methyl-6-(2-phenylethen-1-yl)pyridine (6a) in 32% yield. The yield was 46% from the corresponding solution phase reaction. Compound 6a was converted to the HCl salt. 1H NMR (CD3OD): δ = 8.37-8.32 (1 H, t), 8.19-8.16 (1 H, d), 7.76-7.73 (2 H, m), 7.68-7.65 (1 H, d), 7.52-7.47 (3 H, m), 7.39-7.34 (1 H, d), 2.79 (3 H, s). 13C NMR (CD3OD): δ = 154.14, 151.44, 146.72, 142.34, 135.79, 131.71, 130.12, 129.29, 121.21, 121.79, 118.63, 19.65. ESMS (M + H+): 196. HRMS (MALDI) calcd for C14H13N (M + H) 196.1121. Found: 196.1125.

7

2-Ethyl-6-[( E )-2-phenylethenyl]pyridine ( 6c): 1H NMR (CDCl3): δ = 7.76 (1 H, t), 7.79-7.74 (3 H, m), 7.55-7.32 (5 H, m), 7.16-7.13 (1 H, d), 3.06-2.99 (2 H, q), 1.41-1.36 (3 H, t). 13C NMR (CDCl3): δ = 162.14, 154.06, 138.88, 136.13, 134.79, 128.94, 128.83, 127.50, 125.67, 121.02, 119.09, 30.10, 13.91. ESMS (M + H+): 210. HRMS (MALDI) calcd for C14H13N (M + H): 210.1279. Found: 210.1256.
2-[( E )-2-phenylethenyl]pyridine ( E -6d): 1H NMR (CDCl3): δ = 8.61-8.60 (1 H, d), 7.68-7.57 (4 H, m), 7.40-7.25 (4 H, m), 7.20-7.12 (2 H, m). 13C NMR (CDCl3): δ = 155.62, 149.72, 136.65 (2 C, overlap) 132.74, 128.79, 128.41, 127.95, 127.16, 122.20, 122.14. ESMS (M + H+) 182. HRMS (MALDI) calcd for C13H11N (M + H): 182.0967. Found: 182.0960.
2-[( Z )-2-phenylethenyl]pyridine ( Z -6d): 1H NMR (CDCl3): δ = 8.59-8.57 (1 H, d), 7.46-7.40 (1 H, t), 7.27-7.20 (5 H, m), 7.17-7.15 (1 H, d), 7.10-7.06 (1 H, m), 6.86-6.82 (1 H, d), 6.71-6.67 (1 H, d). 13C NMR (CDCl3): δ = 156.36, 149.59, 136.66, 135.71, 133.31, 130.52, 128.92, 128.35, 127.65, 123.91, 121.83. ESMS (M + H+): 182.
4-Methoxy-2-[( E )-2-phenylethenyl]pyridine ( E -6e): 1H NMR (CDCl3): δ = 8.39-8.37 (1 H, d), 7.65-7.60 (1 H, d), 7.55-7.52 (2 H, d), 7.35-7.32 (2 H, t), 7.27-7.24 (1 H, t), 7.10-7.05 (1 H, d), 6.82-6.81 (1 H, d), 6.61-6.59 (1 H, m), 3.73 (3 H, s). 13C NMR (CDCl3): δ = 166.18, 157.06, 150.81, 136.55, 132.80, 128.76, 128.39, 127.94, 127.15, 108.39, 108.15, 55.06. ESMS (M + H+): 212. Anal. Calcd for C14H13NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.20; H, 6.08; N, 6.60.
4-Methoxy-2-[( Z )-2-phenylethenyl]pyridine ( Z -6e): 1H NMR (CDCl3) δ = 8.39-8.37 (1 H, d), 7.29-7.23 (5 H, m), 6.85-6.81 (1 H, d), 6.68-6.61 (3 H, m), 3.55 (3 H, s). 13C NMR (CDCl3): δ = 165.62, 158.08, 150.94, 137.08, 133.74, 131.03, 129.27, 128.72, 128.01, 109.53, 109.40, 55.17. ESMS (M + H+): 212.
4-Hydroxy-2-[( E )-2-phenylethenyl]pyridine [ E -6f): 1H NMR (CD3OD): δ = 7.78-7.75 (1 H, d), 7.62-7.59 (2 H, d), 7.44-7.33 (4 H, m), 7.02-6.96 (1 H, d), 6.65-6.64 (1 H, d), 6.42-6.39 (1 H, dd). 13C NMR (CD3OD) δ = 181.75, 149.20, 140.10, 136.74, 136.54, 130.63, 130.08, 128.50, 121.61, 116.63, 115.30. ESMS (M + H+): 198. HRMS (MALDI) calcd for C13H11NO (M + H): 198.0913. Found: 198.0916.
4-Methyl-2-[( E )-2-phenylethenyl]pyridine [ E -6g): 1H NMR (CDCl3) δ = 8.51-8.49 (1 H, d), 7.60-7.55 (1 H, d), 7.53-7.50 (2 H, d), 7.40-7.35 (3 H, m), 7.15-7.13 (1 H, d), 6.82-6.81 (1 H,d), 6.61-6.59 (1 H, m), 2.15 (3 H, s). ESMS (M + H+): 196. HRMS (MALDI) calcd for C14H13N (M + H): 196.1121. Found: 196.1125.
4-Methyl-2-[( Z )-2-phenylethenyl]pyridine [ Z -6g): 1H NMR (CDCl3) δ = 8.57-8.55 (1 H, d), 7.29-7.23 (5 H, m), 6.85-6.81 (1 H, d), 6.75-6.71 (1 H, d), 6.68-6.61 (2 H, m), 2.12 (3 H, s). ESMS (M + H+): 196. HRMS (MALDI) calcd for C14H13N (M + H): 196.1121. Found: 196.1121.
3-Methoxy-2-[( E )-2-phenylethenyl]pyridine ( E -6h): 1H NMR (CDCl3) δ = 8.22-8.20 (1 H, m), 7.80-7.75 (1 H, d), 7.64-7.61 (2 H,m), 7.62-7.57 (1 H, d), 7.38-7.33 (2 H, t), 7.29-24 (1 H, t), 7.14-7.12 (2 H, m), 3.86 (3 H, s). 13C NMR (CDCl3) δ = 153.09, 145.29, 141.15, 137.33, 132.69, 128.68, 128.12, 127.28, 122.81, 121.72, 117.76, 55.43. ESMS (M + H+): 212. HRMS (MALDI) calcd for C14H13NO (M + H): 212.7010. Found: 212.1074. Anal. Calcd for C14H13NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.20; H, 6.09; N, 6.38.
3-Methoxy-2-[( Z )-2-phenylethenyl]pyridine ( Z -6h): 1H NMR (CDCl3) δ = 8.14-8.12 (1 H, dd), 7.24-7.12 (7 H, m), 6.81-6.77 (1 H, d), 6.74-6.70 (1 H, d), 3.66 (3 H, s). 13C NMR (CDCl3) δ = 153.39, 146.50, 140.89, 137.10, 133.73, 128.95, 127.84, 127.44, 125.16, 123.14, 117.54, 55.22. ESMS (M + H+): 212.
3-Methyl-2-[( E )-2-phenylethenyl]pyridine ( E -6i): 1H NMR (CD3OD) δ = 8.32-8.33 (1 H, d), 7.62-7.57 (4 H, m), 7.43-7.27 (4 H, m), 7.18-7.14 (1 H, m), 2.43 (3 H, s). 13C NMR (CDCl3) δ = 153.67, 146.52, 139.00, 137.08, 134.27, 131.93, 128.74, 128.46, 127.13, 123.72, 122.52, 17.83. ESMS (M + H+): 196. HRMS (MALDI) calcd for C14H13N (M + H): 196.1121. Found: 196.1116. Anal. Calcd for C14H13NO: C, 86.12; H, 6.71; N, 7.17. Found: C, 86.24; H, 6.87; N, 7.17.
3-Methyl-2-[( Z )-2-phenylethenyl]pyridine ( Z -6i): 1H NMR (CD3OD) δ = 8.44-8.42 (1 H, dd), 7.45-7.42 (1 H, dd), 7.15-7.08 (4 H, m), 7.05-7.01 (2 H, m), 6.80-6.76 (1 H, d), 6.70-6.66 (1 H, d), 2.10 (3 H, s). 13C NMR (CDCl3) δ = 156.67, 146.84, 139.68, 137.41, 134.39, 133.20, 129.42, 129.03, 128.38, 128.10, 123.58, 18.32. ESMS (M + H+): 196.
2-Methyl-6-vinylpyridine ( 6j): 1H NMR (CD3OD) δ = 8.33-8.28 (1 H, t), 8.02-8.00 (1 H, d), 7.67-7.65 (1 H, d), 6.95-6.86 (1 H, dd), 6.50-6.44 (1 H, d), 5.96-5.93 (1 H, d), 2.68 (3 H, s). 13C NMR (CDCl3) δ = 155.00, 151.20, 147.50, 128.96, 128.27, 127.57, 122.06, 19.62. GCMS (EI): 119.
2-Methyl-6-[(1 E )-prop-1-enyl]pyridine ( E -6k): 1H NMR (CD3OD) δ = 8.38, 8.32 (1 H, t), 8.05-8.02 (1 H, d), 7.70-7.67 (1 H, d), 7.24-7.16 (1 H, m), 6.77-6.72 (1 H, d), 2.78 (3 H, s), 2.09 (3 H, d). 13C NMR (CDCl3) δ = 154.18, 151.85, 147.10, 143.45, 126.24, 123.13, 121.60, 19.56, 19.40. GCMS (EI): 133.
2-Methyl-6-[(1 Z )-prop-1-enyl]pyridine ( Z -6k): 1H NMR (CD3OD) δ = 8.47, 8.42 (1 H, t), 7.94-7.91 (1 H, d), 7.79-7.76 (1 H, d), 6.70-6.66 (1 H, d), 6.62-56 (1 H, m), 2.81 (3 H, s), 2.07 (3 H, d). 13C NMR (CDCl3) δ = 158.56, 155.05, 147.21, 141.50, 126.63, 125.45, 121.66, 19.71, 15.50. GCMS (EI): 133.